Country-wide medical records infer increased allergy risk of gastric acid inhibition
of Proton Pump Inhibitors (PPI - such as Omeprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, Pantoprazole and Rabeprazole), Sucralfate, H2-receptor antagonists (such as Cimetidine, Ranitidine, Famotidine, Nizatidine, Roxatidine, Lafutidine, Lavoltidine and Niperotidine), and prostaglandin E2 (Dinoprostone
of Proton Pump Inhibitors (PPI - such as Omeprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, Pantoprazole and Rabeprazole), Sucralfate, H2-receptor antagonists (such as Cimetidine, Ranitidine, Famotidine, Nizatidine, Roxatidine, Lafutidine, Lavoltidine and Niperotidine), and prostaglandin E2 (Dinoprostone